[HTML][HTML] Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are
standard of care for EGFR mutation-positive non-small cell lung cancer (NSCLC). However …
standard of care for EGFR mutation-positive non-small cell lung cancer (NSCLC). However …
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1
M Nishio, Y Ohe, S Ikeda, T Yokoyama… - International Journal of …, 2023 - Springer
Abstract Background In CheckMate 227 Part 1 (NCT02477826), first-line nivolumab plus
ipilimumab demonstrated long-term durable overall survival (OS) benefit versus …
ipilimumab demonstrated long-term durable overall survival (OS) benefit versus …
Design, synthesis and biological evaluation of a series of dianilinopyrimidines as EGFR inhibitors
L Yan, Q Wang, L Liu, Y Le - Journal of Enzyme Inhibition and …, 2022 - Taylor & Francis
This paper described our efforts to develop dianilinopyrimidines as novel EGFR inhibitors.
All the target compounds were tested for inhibitory effects against wild type EGFR (EGFRwt) …
All the target compounds were tested for inhibitory effects against wild type EGFR (EGFRwt) …
A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer
Background The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
are a first-line therapy for non-small cell lung cancer (NSCLC) with EGFR mutations …
are a first-line therapy for non-small cell lung cancer (NSCLC) with EGFR mutations …
The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta …
L Guo, G Zhou, M Huang, K Tang… - The Clinical …, 2024 - Wiley Online Library
Background Previous studies have suggested that loss of the EGFR T790M gene mutation
may contribute to the development of resistance to Osimertinib in non‐small cell lung cancer …
may contribute to the development of resistance to Osimertinib in non‐small cell lung cancer …
Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
H Hu, S Tan, M Xie, P Guo, Q Yu, J Xiao… - Frontiers in …, 2023 - frontiersin.org
In non-small cell lung cancer (NSCLC), two key genetic alterations, epidermal growth factor
receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements, are …
receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements, are …
[HTML][HTML] First-line nivolumab+ ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients
KJ O'Byrne, KH Lee, SW Kim, K Park, M Nishio… - ESMO open, 2022 - Elsevier
Background Nivolumab plus ipilimumab demonstrated clinically meaningful improvement in
efficacy versus chemotherapy with a manageable safety profile in patients with advanced …
efficacy versus chemotherapy with a manageable safety profile in patients with advanced …
[HTML][HTML] Sequential afatinib and osimertinib in Asian patients with EGFR mutation-positive non-small cell lung cancer and acquired T790M: combined analysis of two …
S Miura, HA Jung, SY Lee, SH Lee, MK Lee… - OncoTargets and …, 2022 - ncbi.nlm.nih.gov
Objective Two recent non-interventional trials, GioTag and UpSwinG, demonstrated
encouraging time-to-treatment failure (TTF) and overall survival (OS) in patients with …
encouraging time-to-treatment failure (TTF) and overall survival (OS) in patients with …
[HTML][HTML] Real-world study of osimertinib in Korean patients with epidermal growth factor receptor T790M mutation–positive non–small cell lung cancer
JH Lee, EY Kim, CK Park, SY Lee, MK Lee… - Cancer Res …, 2023 - synapse.koreamed.org
Purpose Although osimertinib is the standard-of-care treatment of epidermal growth factor
receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence …
receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence …
Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
R Liu, J Zhou, X Ling - Clinical Medicine Insights: Oncology, 2022 - journals.sagepub.com
Patients from Asia with non-small-cell lung cancer (NSCLC) often have mutations in the
epidermal growth factor receptor (EGFR) gene. While an increasing number of EGFR …
epidermal growth factor receptor (EGFR) gene. While an increasing number of EGFR …